Novo Nordisk shares drop more than 10% over the week
According to CNBC Technology, Novo Nordisk shares have dropped more than 10% this week, on track for their worst performance since February, while Eli Lilly shares have climbed about 2.5%. The report notes Novo’s plan to diversify beyond its weight loss drugs with a broader pipeline, and mentions Lilly’s uptake of its GLP-1 therapy Foundayo.
Key facts
- 01Novo Nordisk stock has fallen more than 10% for the week, on track for its worst performance since February.
- 02Eli Lilly shares have risen about 2.5% in the same period.
- 03Novo Nordisk plans to diversify beyond obesity and diabetes with a pipeline of other drugs.
- 04Lilly CEO Dave Ricks said one-third of new GLP-1 patients are taking Foundayo.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.